Additionally, there are investigational approaches to restoring TP53 function, including small-molecule reactivators of TP53 and adenoviral transfection, which offer the potential to improve outcomes in patients with TP53-mutant HCC. This evidence concerns the gene TP53 and hepatocellular carcinoma.